LENZ Therapeutics (NASDAQ:LENZ) Rating Reiterated by Leerink Partnrs

Leerink Partnrs reissued their outperform rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report report published on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

Other equities analysts have also issued research reports about the stock. SVB Leerink started coverage on shares of LENZ Therapeutics in a research report on Monday. They set an outperform rating and a $32.00 price objective for the company. Citigroup began coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They issued a buy rating and a $34.00 price target on the stock. Piper Sandler started coverage on shares of LENZ Therapeutics in a research report on Wednesday, March 27th. They set an overweight rating and a $28.00 target price on the stock. Finally, William Blair started coverage on shares of LENZ Therapeutics in a research report on Monday. They issued an outperform rating on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of Buy and an average target price of $31.33.

LENZ Therapeutics Price Performance

Shares of NASDAQ LENZ opened at $17.70 on Monday. The firm has a market capitalization of $147.26 million, a PE ratio of -1.13 and a beta of 0.20. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82.

Insider Activity

In related news, Director Ra Capital Management, L.P. bought 998,009 shares of the firm’s stock in a transaction on Thursday, March 21st. The shares were bought at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the transaction, the director now directly owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.